Epstein Secrets

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees - 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACART CAPITAL LLC EFTA_R1_01138845 EFTA02295571 Return on Investment X

.00 36.2% IRR $6.88 DACART CAPITAL LIC EFTA_R1_01138846 EFTA02295572 Advisory Board Thomas Shenk, Ph.D. Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipient of the Eli Lilly Award from the American Society of Microbiology, an American Cancer Soci

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506150 Return on Investment Xenogen Jan-98

r 1 .UU nn 36.2% IRR 4)O& / nn .OO DiNGART C_APIIAL LL, EFTA00506151 Advisory Board Thomas Shenk, • Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipient of the Eli Lilly Award from the American Society of Microbiology, an American Cancer Soci

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506197 Advisory Board Thomas Shenk, • Dr. S

return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506197 Advisory Board Thomas Shenk, • Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipient of the Eli Lilly Award from the American Society of Microbiology, an American Cancer Soci